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Abstract
Background: Multiple sclerosis (MS) is a chronic autoimmune disease characterized by inflammatory and
neurodegenerative processes leading to irreversible neurological impairment. Brain atrophy occurs early in the
course of the disease at a rate greater than the general population. Brain volume loss (BVL) is associated with
disability progression and cognitive impairment in patients with MS; hence its value as a potential target in
monitoring and treating MS is discussed.
Methods: A group of MS neurologists and neuro-radiologists reviewed the current literature on brain atrophy and
discussed the challenges in assessing and implementing brain atrophy measurements in clinical practice. The panel
used a voting system to reach a consensus and the votes were counted for the proposed set of questions for
cognitive and brain atrophy assessments.
Results: The panel of experts was able to identify recent studies, which demonstrated the correlation between BVL
and future worsening of disability and cognition. The current evidence revealed that reduction of BVL could be
achieved with different disease-modifying therapies (DMTs). BVL provided a better treatment and monitoring
strategy when it is combined to the composite measures of “no evidence of disease activity” (NEDA). The panel
recommended a set of cognitive assessment tools and MRI methods and software applications that may help in
capturing and measuring the underlying MS pathology with high degree of specificity.
Conclusion: BVL was considered to be a useful measurement to longitudinally assess disease progression and
cognitive function in patients with MS. Brain atrophy measurement was recommended to be incorporated into the
concept of NEDA. Consequently, a consensus recommendation was reached in anticipation for implementation of
the use of cognitive assessment and brain atrophy measurements on a regional level.
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Background
MS affects over 2.5 million people worldwide, mainly
female adults [1]. In the Middle East and North
Africa region, the overall MS prevalence was reported
to be 51.52/100,000 [2]. MS is characterized by
inflammation and neurodegeneration resulting in
irreversible neurological impairment [3, 4]. The acute
inflammation component, which occurs during the
early phases of the disease, is responsible for the re-
lapses whereas the progressive phase is characterized
by the axonal damage leading to accumulation of
disability. In addition, brain atrophy occurs in all
stages of MS, starting at early stages and progresses
throughout the course of the disease at a higher rate
than atrophy associated with the normal aging
process of healthy individuals [5]. Several disease
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modifying therapies (DMTs) have shown better
efficacy in reducing the clinical and radiological ac-
tivities which may potentially halt the accumulation
of axonal damage and consequently reduce the rate of
BVL [6–8]. Recent studies have prompted debates
about the clinical relevance of BVL over time as a
measure to quantify neurodegeneration. Measuring
brain atrophy through magnetic resonance imaging
(MRI) new techniques and software applications
development allows better and reliable assessments of
brain volume, monitors changes longitudinally, and
assesses treatment effects that could be implemented
in the routine clinical practice [9].
Methods
A group of thirteen neurologists and neuro-radiologists
with expertise in MS from Bahrain, Jordan, Kuwait,
Oman, Qatar, and Spain met to address the unmet needs
of assessing brain atrophy in patients with MS, discuss
the relevant parts of the brain in terms of disease pro-
gression with MS. A comprehensive literature search
was performed of MEDLINE, EMBASE, and Cochrane
databases, systematically reviewing all manuscripts be-
tween January 1st, 1995 and May 10th, 2016. The panel
identified the relevant literature, using the following
MeSH terms: ‘Disease Modifying therapies’ AND ‘mul-
tiple sclerosis’ AND ‘brain atrophy’. Additional searches
were performed of American Academy of Neurology
(AAN) and European Committee for Treatment and Re-
search in Multiple Sclerosis (ECTRIMS) abstracts for
the last two years, using identical search strategies on
their respective websites. The recent updates and emer-
ging data in measuring BVL and its clinical relevance
were discussed. Different MRI-based methods, protocols,
and the challenges in applying them into clinical practice
were reviewed with emphasis on the emerging data of
immediate and long-term effects of DMTs on brain atro-
phy. A voting system was followed by the panel to reach
a consensus and the votes of the experts were counted
for the proposed set of questions for each assessment.
The consensus was based on the highest number of votes
for each single question of each assessment. Finally, a con-
sensus recommendation on how brain volume and cogni-
tion need to be assessed and implemented in clinical
practice on a regional level was developed.
Results
Implications of brain volume loss in MS and unmet needs
MS causes focal and diffuse damage to the brain. The
focal white matter lesions are the classic hallmark of MS
and appear on MRI as T2, gadolinium enhanced T1 le-
sions, or T1-hypointense lesions (black holes) [10]. The
damage also occurs in grey matter as well as diffusely in
normal appearing white matter and consequently lead to
BVL [11, 12]. Among MRI measures, BVL in MS is con-
sidered as one of the prognostic measures which has
been directly correlated with cognitive impairment [13,
14], disability progression [15–17], and fatigue [18]. A
number of longitudinal studies showed that BVL pre-
dicts future worsening of disability and cognition. A 10-
year follow-up study demonstrated that brain atrophy
occurred throughout the course of the disease and was
more severe in the group that showed disability progres-
sion at 5 years of follow-up. Furthermore, it was demon-
strated that the overall grey matter atrophy was a better
predictor of disease progression than white matter atro-
phy during the same follow-up period [19]. In a 13-year
follow-up of 75 MS patients, Fillipi et al. showed that
grey matter damage was associated with significant
worsening of disability and cognitive function in 66%
and 34% of patients, respectively [20]. In a study of 261
MS patients, brain atrophy and lesion load were
complimentary predictors of long term disability over a
10-year follow-up period [21]. BVL has been observed at
the early phases of the disease in patients with clinically
isolated syndrome (CIS) [5].
With respect to age, it has been largely known that after
adolescence, grey matter volume starts to decline in a lin-
ear way (−0.09%/year) while white matter decline starts
after midlife, and at a higher rate (−0.2%/year) [22, 23].
Regarding cortical thickness, at midlife a global thinning
was apparent, spreading over several cortical regions [24].
The decline in the thickness measured was around
0.016 mm/decade. Both volumetric and cortical thickness
age-associated changes had been described, implying that
age is a variable that should be considered when assessing
global or regional brain volume in MS patients.
There were few reported studies exploring potential
gender-associated differences and brain size. Men had lar-
ger grey and white matter volumes compared to women
although after adjusting by total intracranial volume, these
differences disappeared [22]. Regarding cortical thickness,
men showed slightly larger cortical thickness compared to
females only at midlife, and the rate of progressive thin-
ning was similar for both groups [24]. A recent study re-
ported that cortical thickness was associated with total
intracranial volume, but not with gender [25]. Since gen-
der and total intracranial volume are highly correlated, it
is a matter of debate whether one or both variables should
be considered when assessing global or regional brain vol-
ume in MS patients [26, 27].
The participants also identified several unmet needs
regarding brain volume measurements and its imple-
mentation in the routine clinical practice (Table 1).
Assessment of brain volume in patients with MS
Conventional MRI techniques are considered the gold
standard for diagnosing and monitoring the response to
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treatment in patients with MS. However, conventional
MRI has limited specificity and correlation with disabil-
ity measures [28, 29]. In addition, conventional MRI
does not offer any information about the ongoing degen-
erative/reparative processes. Therefore, the panel dis-
cussed the current MRI methods and software
applications that help in capturing and measuring the
underlying MS pathology with high degree of specificity.
Currently, segmentation- and registration-MRI based
methods are used to measure brain volume. The
segmentation-based method such as brain parenchymal
fraction (BPF), white matter fraction (WMf), grey matter
fraction (GMf), and normalized brain volume (NBV)
provide assessment of global (BPF, NBV) or regional
(WMf, GMf) brain volume at a single time-point in an
automated way [28–31]. However, the data extracted out
of this method is usually heterogeneous and influenced
by the quality of T1-weigthed images acquired, and are
not recommended for longitudinal analysis. Registration-
based methods measure brain volume at two time
points, in order to calculate the percentage brain volume
change (PBVC). These methods are robust, sensitive to
changes over time, less influenced by the disruption of
the quality of MR imaging acquisitions, and are most
suitable for evaluating global brain volume changes but
are not usually designed to analyse regional volume
changes over time [32]. The sensitivity and the specifi-
city could vary according to the cut-off value that iden-
tify the annualized PBVC. With a cut-off value of 0.4%,
the sensitivity and specificity are 65% and 80%, respect-
ively [32]. The panel listed the advantages and disadvan-
tages for brain volume assessment in patients with MS
(see Table 2.)
Disease-modifying therapies effect on brain volume
It is important to target the neurodegenerative process
in MS patients, in addition to the inflammation compo-
nent. In general, the results of brain volume data vary
from one study to another, which could be attributed to
the different mechanism of action of DMTs, the ability
of these drugs to cross the blood brain barrier and the
heterogeneity of the patient population. In phase III clin-
ical trials, several DMTs demonstrated reduction in the
rate of brain volume loss in relapsing-remitting multiple
sclerosis (RRMS) patients at variable levels with different
response time (Table 3.) [6–8, 33–49]. However, one
should be careful in interpreting data across trials with
different patient population, using different methods in
measuring brain volume. In both placebo-controlled as
well as active comparator trials, most of the DMTs pro-
vided a delayed effect around the second year of treat-
ment with the exception of daclizumab and fingolimod
[6–8, 33–54]. In the FREEDOMS trials, fingolimod dem-
onstrated an effect on brain volume within 6 months of
treatment [6, 8]. The first reported brain atrophy study
with intramuscular (IM) interferon (IFN)-β-1a demon-
strated lower rate of BVL than placebo in the second
year of treatment of RRMS patients (−0.23% IFN-β-1a
compared to −0.51% in the placebo group; p = 0.03) [33].
However, the subcutaneous (sc) IFN-β-1a produced con-
flicting results in both CIS and RRMS patients [33, 34,
50, 51]. Data from placebo controlled trials on sc IFN-β-
1b and BVL in RRMS patients are not published to date
[52, 53]. Glatiramer significantly reduced BVL by 40% at
9–18 months and 25% at 0–18 months compared to pla-
cebo [35]. Three trials compared glatiramer and IFN-β
and showed a marginal reduction in BVL in one study
[36–38]. In two trials, natalizumab increased the rate of
BVL in the first year and then significantly reduced it
versus placebo in the second year [40, 41].
Table 1 A list of unmet needs with brain volume as identified
by the panel
Unmet Needs
1. Applicability of MRI volume measurement in clinical practice
2. Lack of large long-term prospective studies of clinical correlates with
brain volume loss
3. Reliable assessments of cognitive impairment in MS
4. Validation of disease progression parameters with brain volume loss
5. Lack of pathological correlation with brain volume loss
6. Paucity of data on regional brain volume effect in MS
7. Targeting brain volume loss as one of the main outcome measure in
clinical trials
8. Reproducible effectiveness of DMTs in phase III studies on cognitive
impairment
Table 2 Advantages and disadvantages of brain volume
assessment in MS
Advantages
Whole brain atrophy is easy to measure
Brain atrophy is a “summary measure” of the irreversible/destructive
pathological process of MS
Whole brain atrophy is highly reproducible and sensitive to disease-
related
changes
Correlates with disability, cognitive impairment and fatigue
Disadvantages:
End-stage phenomenon
Pseudoatrophy effect (first 6–12 months)
Fluctuations: steroids, hydration
Co-morbidities: smoking, alcohol, high BMI, etc.
MRI technical confounding factors
Time consuming: reimbursement?
Not enough evidence to use atrophy measures to assess and predict
individual treatment response
BMI Body Mass Index
Alroughani et al. BMC Neurology  (2016) 16:240 Page 3 of 9
Teriflunomide failed to demonstrate reduction in the
rate of BVL compared to placebo [42]. Dimethyl fumar-
ate produced a 21% reduction in BVL compared to pla-
cebo in the DEFINE study and failed to show any
statistically significant reduction in BVL in the CON-
FIRM study [43, 44]. In the CARE-MS I and II, alemtu-
zumab reduced the rate of BVL to 24–42% compared to
sc IFN-β-1a [45, 46]. Both the ALLEGRO and the
BRAVO studies reported reduction of brain atrophy with
laquinimod [47, 48]. Daclizumab had a marginal, but a
significant favorable effect on brain atrophy compared to
IM IFN-β-1a [49]. In the three trials (FREEDOMS I & II
and TRANSFORMS), fingolimod also significantly re-
duced BVL to 28–45% and the reduction of brain
Table 3 The effect of DMTs on BVL in RRMS patients in Phase III trials
Drug (REF.) Changes in Brain Volume Loss
Year 0–1 Year 1–2 Year 0–2
IFN-β-1a IM [33] x ✓
55% reduction vs. placebo
x
IFN-β-1a SC [34] - - x




(Eur/Canadian GA trial) 40% reduction vs. placebo
(Eur/Canadian GA trial)
(Eur/Canadian GA trial)
8% reduction vs. sc IFN-β-1a
(REGARD)+
22% reduction vs. sc IFN-β-1a
(REGARD)+
13% reduction vs. IFN-β-1a
(REGARD)
No sig. difference with GA +/−
sc IFN-β-1b
(BEYOND)
No sig. difference with GA +/−.
sc IFN-β-1b
(BEYOND)
No sig. difference with GA +/−
sc IFN-β-1b
(BEYOND
No sig. difference with GA +/−
sc IFN-β-1a
(COMBIRx)
No sig. difference with GA +/−.
sc IFN-β-1a
(COMBIRx)
No sig. difference with GA +/−
sc IFN-β-1a
(COMBIRx)
Natalizumab [40, 41] ✓ x
(AFFIRM)
40% increase vs. placebo
(AFFIRM)
44% reduction vs. placebo
(AFFIRM)
19% increase vs. placebo
(SENTINEL)
x
23% reduction with Natalizumab+




Teriflunomide [42] 37% reduction vs. placebo (TEMSO) 31% reduction vs. placebo (TEMSO)- X
Dimethyl fumarate
[43, 44]
- 21% reduction vs. placebo (DEFINE)
Significant effect (DEFINE)
×‡ (CONFIRM)
✓21% reduction vs. placebo
(DEFINE) × ‡ ()
Alemtuzumab [45, 46] - ✓
24–42% reduction vs IFN-β-1a
Laquinimod [47, 48] - - ✓ (ALLEGRO)
33% reduction vs placebo
(BRAVO)
28–34% reduction vs placebo
Daclizumab [49] ✓ ✓ -
Significant effect
(Week 0–24)
9% reduction vs IM IFN-β-1a
Significant effect
(Week 24–96)
7% reduction vs IM IFN-β-1a
Fingolimod [6–8] ✓ ✓ ✓
23–40% reduction vs placebo 28–45% reduction vs placebo 33–35% reduction vs placebo
✓§
45% reduction vs. IM IFN β-1a (TRANSFORMS)
- -
BID twice daily, TID three times daily, SC subcutaneous, GA Glatiramer acetate, IFN Interferon
– Data not reported/available × No significant effect or not statistically significant ✓ Significant effect
* Not all approved therapies have significant effects on BVL and effects can be delayed until the second year of therapy. + No P value reported †Significant effect
at 9–18 months
‡Significant effect at 6–24 months in DEFINE (only BID, not TID dose arm), but not in CONFIRM study
§Significant effect also seen at 0–6 months
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atrophy was evident early during the course of the
treatment [6–8].
New emerging strategies in MS
The panel discussed incorporating BVL as a key measure
and part of the treatment strategy, which focuses on
achieving no evidence of disease activity (NEDA). The
measures under NEDA-3 were focused on the composite
measures of absence of relapses, disability progression
(based on expanded disability status scale (EDSS)
scores), and MRI activity (new or enlarging of T2 lesion)
[30, 31]. As more evidence is accumulating with respect
to the importance of brain atrophy during different
stages of MS, absence of BVL may be incorporated to
the NEDA measures to be a total of four measures
(NEDA-4). Incorporating BVL in NEDA-4, allows a
more comprehensive and balanced assessment, captur-
ing both focal and diffuse disease activity [55, 56]. In the
pooled analysis of the two FREEDOMS studies with fin-
golimod, patients on fingolimod were 4 times were more
likely to achieve NEDA-4 than those who were on pla-
cebo at two years [57]. The advisors discussed the fol-
lowing case as an example of a patient who achieved a
NEDA-4 during a period of 3 years. A 35-year old fe-
male was diagnosed with MS and had a highly active dis-
ease (more than 20 active lesions) at baseline. A disease
modifying therapy was initiated in 2012. Over the 3-year
longitudinal follow-up, there was no evidence of disease
activity (absence of relapses, disease progression and
MRI new/enlarging lesions). The change in the annual-
ized brain volume change during the observational
period was −0.089, which was below the threshold con-
sidered in NEDA 4 of −0.4% (Fig. 1).
Cognitive assessment consensus
The panel acknowledged that cognitive ability is not
readily observable in routine neurological examinations,
and self-reported cognitive complaints are confounded
by mood and other subjective symptoms. One of the
core cognitive deficits in MS patients is slowing of infor-
mation processing speed, which can be subtle and diffi-
cult to assess without formal neuropsychological testing.
In addition, there is a problem with the testing-retesting
reliability as well as confounders at the time of testing.
The advisors listed the most common tools that are uti-
lized for cognitive assessment in their clinical practice
such as the BICAMS (Brief International Assessment for
Cognition for MS), CDT (The Clock Drawing Test), the
MSNQ (MS Neuropsychological Screening Question-
naire), the PASAT (The Paced Auditory Serial Addition
Task), the SDMT (Symbol Digit Modalities Test), and fi-
nally the WLG (Word List Generation) (Table 4.).
The panel utilized a standard format of questions for
assessing cognition, including; 1) the types of tools they
would use to test cognitive assessment, 2) the types of
MS patients in whom they would apply these tests 3) the
timing of the assessment 4) where they would apply
these tests 5) and finally who would apply these tools.
They used a voting system to rate and highlight the im-
portance and the clinical relevance of each cognition as-
sessment test the in the real world setting. Each voting
participant could vote multiple times for different
categories.
Of the 12 expert voting panel, 75% voted for the
Symbol Digit Modalities Test (SDMT) as the most com-
mon test they would utilize for cognition. All voted to
use the SDMT in RRMS and equal distribution of votes
for the rest of the MS spectrum. All of the advisors rec-
ommended to have the assessment test at 12 months
during the office visit and 83% of the experts recom-
mended the tools to be conducted by the nurse, since it
is time consuming for most neurologists (Table 4).
Brain volume assessment consensus
The advisors utilized the same methodology for asses-
sing brain volume, including; 1) the types of methods
they would use to assess BVL, 2) the types of MS pa-
tients they would target 3) the timing of the assess-
ment during disease activity 4) and who would
conduct these studies. They also used a voting system
to rate importance and the clinical applicability of
these methods in the routine clinical practice and
each voting member was able to vote multiple times
for different categories.
As for the brain volume assessment (Table 5.), all
(100%) of the advisors recommended the Structural
Image Evaluation, using Normalization, of Atrophy
(SIENA), a registration-based method, to measure BVL
mainly in patients with radiologically isolated syndrome
(RIS), CIS, & RRMS at the 6–12 month time frame for
most participants. It was recommended to have this
measurement taken by the MRI technician.
Discussion
The expert panel considered BVL a relevant measure of
diffuse damage and global marker for neuronal loss and
also considered BVL to be a useful measurement to fol-
low up patients with MS. The panel acknowledged that
there are several confounders that should be taken into
consideration before interpreting the results of these
methods. The challenges include issues such non-
standardization, variability, high technical expertise and
infrastructure requirements, the availability of resources
to perform the post-processing comparisons of the im-
ages, cost and reimbursements. In addition, there are
MRI-related factors, for example variation in imaging
protocols, artifacts such as signal heterogeneity,
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spatial distortions, motion, and the lack of normative
data acquired with the same MR protocol. Other
confounding factors include pseudoatrophy effect
(BVL secondary to reduction in inflammation due to
DMTs), and other non-MS related factors such as
high body mass index, genetic factors, high alcohol
consumption, smoking, dehydration, and cardiovascu-
lar risk factors [30, 31]. These challenges should be
addressed before considering the implementation of
these methods into clinical practice.
Currently, brain atrophy is not measured routinely in
clinical practice to longitudinally assess the clinical pro-
gression and monitor treatment. Furthermore, brain at-
rophy measurement requires standardization of MRI
acquisition and software techniques to allow proper
comparisons at different time points during disease
process. As mentioned previously, one should be aware
of the DMT-induced pseudoatrophy effect, particularly,
relevant in the first few months of treatment and it is
more evident with highly anti-inflammatory DMTs. This
phenomena is mainly seen in the white matter [30, 31].
The panel also recognized the importance of BVL
as a cornerstone of measurement in NEDA-4 in the
clinical progression and monitoring of MS, which
should lead to improvement in treatment strategies
and patient outcomes. As a result, the advisors rec-
ommended conducting further validation of NEDA-4
on a regional level to determine whether patients
who achieve the four measures in NEDA-4 are at
lower risk of future disability than those with disease
activity or those achieving NEDA-3.
The panel agreed on the need for a consensus recom-
mendation to share knowledge and opinions among ex-
perts in the field in order to unify aspects of clinical and
radiological assessments. In addition, the advisors’ aspir-
ation to deliver stronger messages to local neurologists
may lead to ultimately improve the overall care of pa-
tients. The rationale for the consensus recommendations
is not to focus on the inflammatory component but
rather, to understand the neurodegenerative compo-
nent of the disease process and to implement strat-
egies to assess cognitive functions and brain atrophy
over time. Studying the evolution and longitudinal
changes of cognition and brain volume over time may
shed light on different aspects of disease progression
and the overall natural history of disease. The current
diagnostic criteria lack any relevance to the neurode-
generative aspects and concentrate mainly on the
Fig. 1 Illustration of a longitudinal effect of treatment on brain parenchymal fraction. (Source: Dr. Rovira; data on file)
Table 4 The tally of cognition assessment
How? SDMT BICAMS PASAT WLG CDT
9 3 4 1 4
In Whom? RIS CIS RRMS SPMS
7 8 12 8
When? Initial 3–6 months 12 months
2 1 12
Where? Office Home Waiting area
12 1 0
Who? Physician Nurse Assistant Automated
1 10 4 3
Abbreviations: BICAMS (Brief International Cognitive Assessment for MS), CDT
(The Clock Drawing Test), PASAT (The Paced Auditory Serial Addition Task),
Symbol Digit Modalities Test (SDMT), WLG (Word List Generation)
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inflammatory process. Indeed, the panel acknowledged
that cognition and brain volume assessments might
contribute to the overall treatment strategy.
Conclusion
BVL occurs early and continues throughout the course
of MS. It is considered to be a valid outcome measure to
assess brain tissue loss and one of the best prognostic
parameters of disability progression over the long term
in patients with MS. BVL is accelerated in MS and cor-
relates with disability and cognitive decline. Incorporat-
ing BVL to the composite measures of NEDA-3 is a shift
in treatment and monitoring strategy to ultimately im-
prove patient outcome measures. Advanced imaging and
processing techniques will enable neurologists to probe
diffuse changes in MS along with the clinical endpoints
to monitor changes and ultimately improve treatment.
Considerations should be made prior to system wide im-
plementation of BVL measurement in clinical practice.
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Table 5 The tally of brain volume assessment
How? SIENA SIENAx BPF VBM
12 4
In Whom? RIS CIS RRMS SPMS
7 11 12 4
When? Initial 3–6 months Anytime with
MRI acquisition
6–12 months Annual
3 2 11 1
Who? Neurologist Radiologist MRI Technician Independent
1 12 1
Abbreviations: BPF (Brain Parenchymal Fraction), SIENA (Structural Image Evaluation, using Normalization, of Atrophy), SIENAx (Structural Image Evaluation, using
Normalization, of Atrophy Cross-sectional), VBM (Voxel-Based Morphometry)
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